



The sustained power of HUMIRA:

Helps patients with Crohn's disease maintain clinical remission

In the CHARM study:


- 40% of patients taking HUMIRA every other week (n=172) were in clinical remission* at week 26 vs 17% of placebo patients (n=170; $P<0.001$)^{1,2†}
- 36% of patients taking HUMIRA every other week were in clinical remission* at week 56 vs 12% of placebo patients ($P<0.001$)^{1,2†}

*Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score <150 points.

81% of patients treated with HUMIRA EOW who were in remission at week 26 (n=68) remained in remission at week 56 (n=55)^{2,3}

- 42% of anti-TNF naïve patients receiving HUMIRA every other week achieved clinical remission (CDAI <150) at 56 weeks^{2,3}

Clinical remission rates in anti-TNF naïve patients (randomised responders)^{2,3†}



†The above analysis is of the ITT study population. Patients with missing data were classified as not in clinical remission.

HUMIRA is indicated for treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

For induction treatment, HUMIRA should be given in combination with corticosteroids. HUMIRA can be given as monotherapy in case of intolerance to corticosteroids or when continued treatment with corticosteroids is inappropriate.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Abbott on 0800 121 8267.

Prescribing information is available from this stand.

References: 1. HUMIRA Summary of Product Characteristics, August 2009. 2. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007;132:52-65. 3. Data on file. Abbott Laboratories, RM15061.

AXHUG092615

Date of Preparation: September 2009

HUMIRA

adalimumab

SUSTAINABLE IMPACT



A Promise for Life